Israel - hebraisk - Ministry of Health

ישרדרם - לחות לפנים

Israel - hebraisk - Ministry of Health

ישרדרם - לחות לפנים

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - gabapentin - tablet, film coated - excipient ingredients: hyprolose; mannitol; crospovidone; purified talc; magnesium stearate; poloxamer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gabaran is indicated for the maintenance treatment of, partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabaran is also indicated for the maintenance treatment of neuropathic pain

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - gabapentin - tablet, film coated - excipient ingredients: hyprolose; mannitol; crospovidone; purified talc; magnesium stearate; poloxamer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gabaran is indicated for the maintenance treatment of, partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabaran is also indicated for the maintenance treatment of neuropathic pain

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - gabapentin - tablet, film coated - excipient ingredients: hyprolose; mannitol; crospovidone; purified talc; magnesium stearate; poloxamer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gabaran is indicated for the maintenance treatment of, partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabaran is also indicated for the maintenance treatment of neuropathic pain

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - gabapentin - tablet, film coated - excipient ingredients: hyprolose; mannitol; crospovidone; purified talc; magnesium stearate; poloxamer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gabaran is indicated for the maintenance treatment of, partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabaran is also indicated for the maintenance treatment of neuropathic pain

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - entecavir, quantity: 1 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; povidone; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - baraclude is indicated for the treatment of chronic hepatitis b virus infection infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment naive and lamivudine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - entecavir, quantity: 0.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; povidone; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - baraclude is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment naive and lamivudine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Den europeiske union - bulgarsk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - Энтекавир - Хепатит В, хроничен - Антивирусни средства за системно приложение - baraclude е показан за лечение на хроничен вируса на хепатит В (hbv-инфекция) при възрастни с:компенсированным заболяване на черния дроб и признаци на активна вирусна репликация, постоянно повишено ниво на аланинаминотрансферазы (alt) и гистологических признаци на активно възпаление и/или фиброза;декомпенсированные заболявания на черния дроб. Като компенсированные и декомпенсированные заболявания на черния дроб, този индекс се базира на данни от клинични проучвания при наивни пациенти нуклеозидов с положителен резултат на теста за hbeag и hbeag-отрицателен hbv-инфекция. По отношение на пациентите с рефрактерен на ламивудин хепатит В.

Den europeiske union - maltesisk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - entecavir - epatite b, kronika - antivirali għal użu sistemiku - baraclude huwa indikat għat-trattament ta kronika tal-virus epatite b (hbv) fl-adulti bil:mard tal-fwied ikkumpensat u evidenza ta 'replikazzjoni virali attiva, persistenti elevati fis-serum alanine aminotransferase (alt) livelli u evidenza istoloġika ta' infjammazzjoni attiva u/jew fibrożi;mard tal-fwied dekompensat. kemm għall-kkumpensati u mard tal-fwied dikumpensat, din l-indikazzjoni hija bbażata fuq tagħrif minn provi kliniċi f'pazjenti li huma nucleoside naïve b'hbeag pożittiv u hbeag negattiv li jaqbadhom infezzjoni hbv. fir-rigward ta 'pazjenti b'epatite b refrattarja għal lamivudine.